Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients

Journal of Infectious Diseases

Volumn 201, Issue 4, 2010, Pages 627-634

  Parra, Sandra ^a   Marsillach, Judit ^a   Aragonés, Gerard ^a   Beltrán, Raúl ^a   Montero, Manuel ^a   Coll, Blai ^b   Mackness, Bharti ^a   Mackness, Michael ^a   Alonso Villaverde, Carlos ^a   Joven, Jorge ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ARYLDIALKYLPHOSPHATASE 1 GENE; ATHEROSCLEROSIS; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROL GROUP; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 75749149310     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650312     Document Type: Article

References (28)

1. Schwarz B. Oxidative stress during viral infection: a review. Free Rad Biol Med 1996; 21:641-649 (Pubitemid 26331094)
2. Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 2008; 56:752-769
3. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009; 46:83-106.
4. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101:1581-1590
5. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423:57-60. (Pubitemid 28098579)
6. Marsillach J, Mackness B, Mackness M, et al. Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Rad Biol Med 2008; 45:146-157
7. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Blatter-Garin MC. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000; 49:1390-1393
8. Wheeler JG, Keavnay BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004; 363:689-695 (Pubitemid 38296555)
9. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Rad Biol Med 2002; 34:774-784 (Pubitemid 36288542)
10. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106:484-490 (Pubitemid 34803695)
11. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004; 318:680-683 (Pubitemid 38624207)
12. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004; 110:2204-2209 (Pubitemid 39372502)
13. Parra S, Alonso-Villaverde C, Coll B, et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007; 194:175-181 (Pubitemid 47464297)
14. Bertran N, Camps J, Fernández-Ballart J, et al. Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. J Lab Clin Med 2005; 145:41-46 (Pubitemid 40139076)
15. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410
16. Gómez F, Camps J, Simó JM, Ferré N, Joven J. Agreement study of methods based on the elimination principle for the measurement of LDL-and HDL-cholesterol compared with ultracentrifugation in patients with liver cirrhosis. Clin Chem 2000; 46:118-121.
17. FerréN,CampsJ,PratsE,etal.Serumparaoxonaseactivity: anewadditionaltestfortheimprovedevaluationofchronicliverdamage.ClinChem2002;48: 261-268(Pubitemid34107262)
18. Gaidukov L, Tawfik DS. The development of human sera tests for HDLbound serum PON1 and its lipolactonase activity. J Lipid Res 2007; 48:1637-1646 (Pubitemid 47312025)
19. Marsillach J, Aragonés G, Beltrán R, et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009; 42:91-98
20. Barrett JC, Fry B, Mailer J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265 (Pubitemid 40202029)
21. Stephens M, Smith N, Donnely P. A new statistical method for haplotypes reconstruction from population data. Am J Hum Genet 2001; 68:978-989 (Pubitemid 32289743)
22. Morcillo-Suarez C, Alegre J, Sangros R, et al. NP analysis to results (SNPator): a web-based environment oriented to statistical genomics analyses upon SNP data. Bioinformatics 2008; 24:1643-1644 (Pubitemid 351966166)
23. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vase Biol 2001; 21:473-480
24. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lip Res 2006; 47:2492-2502
25. Coll B, Parra S, Alonso-Villaverde C, Aragonés G, et al. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007; 38:2477-2484 (Pubitemid 47329625)
26. + T cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615-1624
27. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoproteins and preserved by antioxidants. Free Rad Biol Med 1999; 26:892-904. (Pubitemid 29198362)
28. Ferré N, Camps J, Fernández-Ballart J, et al. Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in general population. Clin Chem 2003; 49:1491-1497 (Pubitemid 37011737)